Reversible protein phosphorylation mediated by kinases and phosphatases plays an important role in cellular function regulations such as cell proliferation, apoptosis, subcellular translocation, inflammation and metabolism. The human kinase group includes 518 known protein kinases and about 20 lipid kinases. As we know that most of the kinase inhibitors target highly conserved ATP-binding sites, and highly selective drugs are pursued in terms of their superior safety profile compared to lower selectivity inhibitors, where lower selectivity drugs have off-target kinases inhibition,  inhibit cancer cell growth by relieving multiple kinase-dependent pathways, and induce toxic side effects in clinic.

  The kinase activity evaluation is critical for biochemical research, clinical diagnosis and drug targeted therapy for serious diseases. The study of a rapid, simple, sensitive and specific method for detecting kinase activity has a wide application prospect, and high-throughput screening (HTS) was used widely developing highly selective inhibitors, and so kinase profiling has become an important standard for the kinase inhibitors evaluation.

The ICE Bioscience has developed a kinase profiling platform based on HTRF and ADP-GLO methods to facilitate the development of new drugs, such as CDK kinase panel (16 types) and TK kinase panel (76 types), 60 mini kinase panel, 207 wild-type kinase panel and 310 kinase panel as shown in the appendix below.

Welcome any further discussion on the assay details and validation data.

Keywords： kinase profiling; Off-target effect; High throughput screening;

Pictures：

Figure 1 FDA-approved kinase inhibitors mapped onto the human kinome

References：

1. Attwood Misty M,Fabbro Doriano,Sokolov Aleksandr V et al. Trends in kinase drug discovery: targets, indications and inhibitor design.[J] .Nat Rev Drug Discov, 2021, 20: 839-861.

Validation data:

Appendix：

Mini kinase panel (60 kinases)
ABL1	CK1γ2	IGF1R	PDGFRα
AKT1	CK1γ3	IKK-alpha	PIM1
ALK 4	CK2a1	ITK	PKACα
AMPKα1/β1/γ1	CLK1	JAK3	PKCα
AurB	DAPK1	JNK1	PKD2
AXL	DCAMKL2	KDR	PLK1
BRAF	DYRK1B	LCK	PLK2
BRSK2	EGFR	MAP2K1	ROCK1
CDK1/CycE1	EPHB4	MAPKAPK2	RSK1
CDK18 < 上一条：激酶谱筛选|激酶谱|药物靶点筛选|爱思益普 全部 下一条：TRPV1受体|癌性疼痛|疼痛模型构建|疼痛模型实验设计|爱思益普 31 2022-08 最新动态 激酶外包实验服务|酶学靶点实验服务|激酶... 2024-09-06 激酶谱检测服务|安全药理学检测实验|酶学... 2024-09-06 激酶谱定制服务|高通量筛选服务|酶学实验... 2024-09-06 激酶谱筛选实验服务|激酶谱分析服务|靶点... 2024-09-06 激酶谱测试服务|激酶谱定制服务|激酶谱实... 2024-09-06 G蛋白偶联受体实验服务|脱靶效应检测服务... 2024-09-04 CRO+ 创新平台 调研咨询 文献汇总 关于我们 公司简介 发展历程 团队管理 实验室VR 人才培养 产品 蛋白产品 研发服务 生物学一体化服务 靶点验证及开发 细胞生物学 靶点类型及筛选 蛋白降解平台 成药性评价 更多 战略合作 蛋白质组学 生信分析 膜蛋白表达 冷冻电镜平台 虚拟筛选 小分子库通量筛选 新闻中心 新闻资讯 爱求索 会议消息 《爱思学院》线上课 爱思人内刊 招贤纳士 招聘人才 员工关怀 扫一扫关注 爱思益普公众号 友情链接： 国家政府网 国家卫健委 中华医学会 易科学 药渡网 Copyright © 2020- 2023爱思益普科技股份有限公司. All rights reserved. 京ICP备18000044号-1 网络：北京网站建设 业务咨询 北京 业务咨询专线：010-6780-9840 联系地址：北京市经济技术开发区科创十三街18号院锋创科技园16号楼 上海 业务咨询专线：010-6780-9840 联系地址：上海市浦东新区蔡伦路780号新技术推广大楼3E5O室 徐州 业务咨询专线：010-6780-9840 联系地址：江苏省徐州市云龙区淮海文博园 二号楼2层 贵州 业务咨询专线：010-6780-9840 联系地址：贵州省贵阳市南明区龙岭路50号 欧美医药产业园一期2号楼 在线留言×